Generic name |
alemtuzumab |
|
---|---|---|
Strength |
12 mg/1.2 mL |
|
Form |
vial |
Special Authority criteria |
Approval period |
---|---|
Initial treatment course (12 mg infused daily for 5 consecutive days): As monotherapy for the treatment of relapsing-remitting multiple sclerosis (RRMS), diagnosed according to the current clinical criteria and magnetic resonance imaging (MRI) evidence, for patients 18 years of age and older who meet ALL of the following criteria:
AND
AND
|
1 treatment course (5 vials)3,4 |
Second treatment course (12 mg infused daily for 3 consecutive days, administered 12 months after the initial treatment course):
AND
|
1 treatment course (3 vials)3,4 |